Table 1.
Characteristics of the patients with residual rectal cancer after preoperative CRT (n=146)
| Characteristic | n | % |
|---|---|---|
| Age at diagnosis (yr) | ||
| Median | 60 | |
| Range | 29-85 | |
| Sex | ||
| Male | 102 | 69.9 |
| Female | 44 | 30.1 |
| Tumor distance from anal verge (cm) | ||
| <5 | 112 | 76.7 |
| ≥5 | 34 | 23.3 |
| Residual tumor size (cm) | ||
| Median | 6.0 | |
| Range | 2.3-10.0 | |
| Clinical T category | ||
| cT2 | 8 | 5.5 |
| cT3 | 121 | 82.9 |
| cT4 | 17 | 11.6 |
| Clinical N category | ||
| cN0 | 17 | 11.6 |
| cN1-3 | 129 | 88.4 |
| Preoperative CEA (ng/mL)a) | ||
| ≤5 | 91 | 66.9 |
| >5 | 45 | 33.1 |
| Tumor regression grade | ||
| 0 | 4 | 2.7 |
| 1 | 21 | 14.4 |
| 2 | 55 | 37.7 |
| 3 | 66 | 45.2 |
| Pathologic TNM stage | ||
| I | 31 | 21.2 |
| II | 68 | 46.6 |
| III | 47 | 32.2 |
| Down-staged after CRT | ||
| No | 54 | 37 |
| Yes | 92 | 63 |
| KRAS mutationa) | ||
| Negative | 76 | 72.4 |
| Positive | 29 | 27.6 |
| BRAF mutationa) | ||
| Negative | 101 | 96.2 |
| Positive | 4 | 3.8 |
CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; TNM, tumor, node, metastasis.
a)
Missing value is included.